12:00 AM
 | 
Nov 11, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Eylea aflibercept ophthalmic solution regulatory update

Regeneron and Bayer submitted regulatory applications in the U.S. and EU seeking to expand the label of Eylea aflibercept to include diabetic macular edema (DME). Bayer, which...

Read the full 114 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >